APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 170 filers reported holding APELLIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,515,000 | -47.3% | 106,632 | +1.0% | 0.03% | -42.4% |
| Q2 2021 | $6,675,000 | +13.5% | 105,624 | -22.9% | 0.06% | +3.5% |
| Q1 2021 | $5,879,000 | -24.8% | 137,019 | +0.3% | 0.06% | -35.2% |
| Q4 2020 | $7,817,000 | +168.7% | 136,654 | +41.7% | 0.09% | +104.7% |
| Q3 2020 | $2,909,000 | -13.5% | 96,415 | -6.4% | 0.04% | -4.4% |
| Q2 2020 | $3,364,000 | -6.0% | 103,013 | -22.8% | 0.04% | -18.2% |
| Q1 2020 | $3,577,000 | -9.2% | 133,518 | +3.7% | 0.06% | +77.4% |
| Q4 2019 | $3,941,000 | +28.7% | 128,696 | +1.3% | 0.03% | +29.2% |
| Q3 2019 | $3,061,000 | -8.7% | 127,056 | -4.0% | 0.02% | -4.0% |
| Q2 2019 | $3,354,000 | +26.6% | 132,351 | -2.6% | 0.02% | +31.6% |
| Q1 2019 | $2,649,000 | +54.6% | 135,848 | +4.5% | 0.02% | +46.2% |
| Q4 2018 | $1,714,000 | -3.1% | 129,973 | +30.7% | 0.01% | +8.3% |
| Q3 2018 | $1,768,000 | -1.0% | 99,413 | +22.5% | 0.01% | 0.0% |
| Q2 2018 | $1,786,000 | – | 81,182 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |